Blog
RSS FeedPosted by Michael Wonder on 27 Apr 2022
Insights from the March 2022 PBAC meeting (part 2)
28 April 2022 The rejection of dostarlimab should not come as a surprise, the rejection of sotorsaib less so. ...
Posted by Michael Wonder on 26 Apr 2022
PBS brings hope to cancer patients
25 April 2022 - Late-stage breast cancer patients, many of them young women, will have access to a life-extending medication ...
Posted by Michael Wonder on 01 Apr 2022
Price slashed for revolutionary $78,000 a year prostate cancer treatment Lynparza
1 April 2022 - A new subsidy for a revolutionary drug is set to benefit thousands of Aussie men with aggressive ...
Posted by Michael Wonder on 29 Mar 2022
Federal budget 2022: more funding for breast cancer drug Trodelvy
29 March 2022 - Against all the odds Sydney mum Alison Day will get to celebrate her daughter’s 12th birthday — ...
Posted by Michael Wonder on 21 Mar 2022
Mum’s fear as promising cancer drug out of reach
21 March 2022 - A terminally ill mum desperate for “more time” with her family was “broken” when she learnt the ...
Posted by Michael Wonder on 15 Mar 2022
Better care and treatment for Australians with blood cancer
15 March 2022 - Australians with blood cancer will receive improved treatment and care through new and continued funding from the ...
Posted by Michael Wonder on 02 Mar 2022
BeiGene hits major milestone with first PBS approved cancer treatment
1 March 2022 - BeiGene is welcoming the listing of Brukinsa (zanubrutinib), a targeted treatment for mantle cell lymphoma, an aggressive ...
Posted by Michael Wonder on 26 Feb 2022
Landmark PBS listing for Australians with leukaemia
25 February 2022 - From 1 March 2022, Australians with acute myeloid leukaemia will have access to a new treatment option ...
Posted by Michael Wonder on 25 Feb 2022
MAP offers new online pathway for accessing cancer treatments
25 February 2022 - Medicines Australia and Rare Cancers Australia yesterday provided pharmaceutical industry stakeholders a preview of a new ...
Posted by Michael Wonder on 19 Feb 2022
Breast cancer drug buying time for terminal women amid push for PBS subsidy
20 February 2022 - Alison Day was given just months to live after being diagnosed with stage four terminal breast cancer ...
Posted by Michael Wonder on 14 Feb 2022
Peter paid $60,000 to boost his cancer survival chances, but others miss out
15 February 2022 - Some cancer patients are dipping into their superannuation to pay for treatments under a “two-tiered system” ...
Posted by Michael Wonder on 31 Jan 2022
Schedule of Pharmaceutical Benefits - 1 February 2022 update
1 February 2022 - The February 2022 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 30 Jan 2022
PBS listing to benefit Australians with rare type of non-Hodgkin lymphoma
31 January 2022 - From 1 February, thousands of Australians with a relapsed and/or refractory mantle cell lymphoma, a form of ...
Posted by Michael Wonder on 30 Dec 2021
PBS listing for Braftovi and cetuximab for metastatic bowel cancer patients with BRAFV600 mutation
30 December 2021 - Pierre Fabre Australia today announced that Braftovi (encorafenib) in combination with cetuximab will be listed on the ...
Posted by Michael Wonder on 17 Dec 2021
Medicine agency recommends listing of life-saving drugs for Australian men with deadly forms of prostate cancer
17 December 2021 - Prostate Cancer Foundation of Australia has welcomed recommendations by Australia’s Pharmaceutical Benefits Advisory Committee to list ...